Advertisement
Table 3 Sensitivity analysis: incremental cost-effectiveness ratio (ICER) of HPV vaccination* in Estonia, model estimates.
| ICER € per QALYs | |
|---|---|
| Base case | 4889 |
| Screening characteristics | |
| Under hypothetical improved cervical screening program** | 6167 |
| Vaccine characteristics | |
| Assuming no HPV 6/11 protection | 5771 |
| Duration of protection = 20 years | 8090 |
| Vaccination characteristics | |
| Low vaccine coverage (70%) | 4444 |
| High vaccine coverage (95%) | 5212 |
| Costs characteristics | |
| Cost of diagnosis and treatment +20% | 4744 |
| Cost of diagnosis and treatment −20% | 5037 |
| Cost of vaccine - 10% | 4351 |
| Cost of vaccine + 10% | 5454 |
| Health utility values | |
| Cost per life year saved (no quality of life adjustments) | 6746 |
| Discount rate | |
| Discount rate 0% | 1517 |
| Discount rate 5% | 11148 |
